We designed a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)–induced metabolic syndrome. We found that the administration of pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over a 12-month period.
Journal Article. 2462 words. Illustrated.
Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology
Full text: subscription required